The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis

Brian Bressler, J. K. Law, N. Al Nahdi Sheraisher, K. Atkinson, M. F. Byrne, H. V. Chung, M. Fishman, N. Partovi, D. Pearson, R. Penner, R. A. Enns

Research output: Contribution to journalArticle

Abstract

Background/aim: The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC. Methods: Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy. Results: Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76%) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62%), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab. Conclusions: In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62% maintained response either as a bridge to azathioprine or maintenance infliximab.

Original languageEnglish (US)
Pages (from-to)937-940
Number of pages4
JournalCanadian Journal of Gastroenterology
Volume22
Issue number11
StatePublished - 2008
Externally publishedYes

Fingerprint

Ulcerative Colitis
Colectomy
Steroids
Therapeutics
Azathioprine
Infliximab
Maintenance
Demography

Keywords

  • Infliximab
  • Medical refractory
  • Severe ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bressler, B., Law, J. K., Sheraisher, N. A. N., Atkinson, K., Byrne, M. F., Chung, H. V., ... Enns, R. A. (2008). The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Canadian Journal of Gastroenterology, 22(11), 937-940.

The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. / Bressler, Brian; Law, J. K.; Sheraisher, N. Al Nahdi; Atkinson, K.; Byrne, M. F.; Chung, H. V.; Fishman, M.; Partovi, N.; Pearson, D.; Penner, R.; Enns, R. A.

In: Canadian Journal of Gastroenterology, Vol. 22, No. 11, 2008, p. 937-940.

Research output: Contribution to journalArticle

Bressler, B, Law, JK, Sheraisher, NAN, Atkinson, K, Byrne, MF, Chung, HV, Fishman, M, Partovi, N, Pearson, D, Penner, R & Enns, RA 2008, 'The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis', Canadian Journal of Gastroenterology, vol. 22, no. 11, pp. 937-940.
Bressler B, Law JK, Sheraisher NAN, Atkinson K, Byrne MF, Chung HV et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Canadian Journal of Gastroenterology. 2008;22(11):937-940.
Bressler, Brian ; Law, J. K. ; Sheraisher, N. Al Nahdi ; Atkinson, K. ; Byrne, M. F. ; Chung, H. V. ; Fishman, M. ; Partovi, N. ; Pearson, D. ; Penner, R. ; Enns, R. A. / The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. In: Canadian Journal of Gastroenterology. 2008 ; Vol. 22, No. 11. pp. 937-940.
@article{5771e67d3dcb46d795365c7a13b360a3,
title = "The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis",
abstract = "Background/aim: The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC. Methods: Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy. Results: Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76{\%}) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62{\%}), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab. Conclusions: In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62{\%} maintained response either as a bridge to azathioprine or maintenance infliximab.",
keywords = "Infliximab, Medical refractory, Severe ulcerative colitis",
author = "Brian Bressler and Law, {J. K.} and Sheraisher, {N. Al Nahdi} and K. Atkinson and Byrne, {M. F.} and Chung, {H. V.} and M. Fishman and N. Partovi and D. Pearson and R. Penner and Enns, {R. A.}",
year = "2008",
language = "English (US)",
volume = "22",
pages = "937--940",
journal = "Canadian Journal of Gastroenterology and Hepatology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "11",

}

TY - JOUR

T1 - The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis

AU - Bressler, Brian

AU - Law, J. K.

AU - Sheraisher, N. Al Nahdi

AU - Atkinson, K.

AU - Byrne, M. F.

AU - Chung, H. V.

AU - Fishman, M.

AU - Partovi, N.

AU - Pearson, D.

AU - Penner, R.

AU - Enns, R. A.

PY - 2008

Y1 - 2008

N2 - Background/aim: The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC. Methods: Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy. Results: Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76%) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62%), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab. Conclusions: In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62% maintained response either as a bridge to azathioprine or maintenance infliximab.

AB - Background/aim: The use of infliximab in severe ulcerative colitis (UC) is established; however, its role in severe acute UC requires clarification. The present multicentre case series evaluated infliximab in hospitalized patients with steroid-refractory severe UC. Methods: Patients from six hospitals were retrospectively evaluated. Data collection included demographics, duration of disease and previous treatments. The primary end point was response to in-hospital infliximab; defined as discharge without colectomy. Results: Twenty-one patients (median age 26 years) were admitted between May 2006 and May 2008 with severe UC requiring intravenous steroids and given infliximab (median time to infusion eight days). Sixteen (76%) patients were discharged home without colectomy; three of these underwent colectomy at a later date. Of the remaining 13 patients (62%), all but two did not require further courses of steroids; six patients had infliximab as a bridge to azathioprine and seven patients were maintained on regular infliximab. Five patients required in-hospital colectomy after the initial infliximab. Conclusions: In this real-life experience of infliximab in patients with steroid-refractory severe UC, infliximab appears to be a viable rescue therapy. The majority of patients were discharged without surgery and 62% maintained response either as a bridge to azathioprine or maintenance infliximab.

KW - Infliximab

KW - Medical refractory

KW - Severe ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=59149105020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149105020&partnerID=8YFLogxK

M3 - Article

C2 - 19018340

AN - SCOPUS:59149105020

VL - 22

SP - 937

EP - 940

JO - Canadian Journal of Gastroenterology and Hepatology

JF - Canadian Journal of Gastroenterology and Hepatology

SN - 2291-2789

IS - 11

ER -